NASDAQ · Biotechnology

BioCardia, Inc. (BCDA) Stock

$1.07 +0.94% NASDAQ: BCDA Healthcare

Valuation

MetricValue
Price$1.07
Market Cap$15.93M
P/E Ratio-1.54
P/B Ratio5.24
P/S Ratio0.00
EPS (TTM)$0.00
52-Week High$1.80
52-Week Low$0.75
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-569.36%
ROA-154.34%
ROCE-273.70%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.11
Current Ratio1.50

Annual Financials (USD)

Metric20212022202320242025
Revenue$1.0M$1.0M$0$0$0
Operating Profit$-13.0M$-12.0M$-12.0M$-8.0M$-8.0M
Net Profit$-13.0M$-12.0M$-12.0M$-8.0M$-8.0M
EPS$-11.19$-10.05$-8.19$-2.90$-1.23
Op Margin-1244.3%-880.3%-2441.1%-13794.8%—

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$16.0M$10.0M$3.0M$4.0M$3.0M
Total Liabilities$5.0M$5.0M$5.0M$3.0M$3.0M
Cash$13.0M$7.0M$1.0M$2.0M$2.0M
Borrowings$2.0M$2.0M$1.0M$1.0M$1.0M

Latest News

Daily – Vickers Top Insider Picks for 07/22/2026 Argus Research · Jul 22, 2026 Daily – Vickers Top Insider Picks for 07/21/2026 Argus Research · Jul 21, 2026 New Strong Sell Stocks for July 14th Zacks · Jul 14, 2026 BioCardia Letter to Stockholders on 2026 Priorities and Strategic Opportunities GlobeNewswire · Jun 18, 2026 BioCardia Announces $4.4 Million Financing GlobeNewswire · Jun 8, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-10.0M$-11.0M$-10.0M$-8.0M$-7.0M
Investing Cash Flow$0$0$0$0$0
Financing Cash Flow$0$0$-1.0M$-1.0M$0
Net Cash Flow$-9.0M$-6.0M$-6.0M$1.0M$0
Free Cash Flow$-10.0M$-11.0M$-10.0M$-8.0M$-7.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.01
EV / EBITDA-2.00
FCF Yield-43.48%
Quick Ratio2.09
Interest Coverage0.00
Return 1Y-61.57%
Return 3Y-97.49%
Return 5Y-98.27%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ACXPAcurx Pharmaceuticals, Inc. $1.27 +1.60% -0.36 $5.46M 0.00%
ADILAdial Pharmaceuticals, Inc $4.04 +1.76% -0.26 $10.61M 0.00%
ALZNAlzamend Neuro, Inc. $1.36 +1.49% -0.60 $5.17M 0.00%
APREAprea Therapeutics, Inc. $0.58 +4.73% -0.64 $7.24M 0.00%
APVOAptevo Therapeutics Inc. $1.81 +0.56% -0.01 $3.96M 0.00%

About BioCardia, Inc.

BioCardia, Inc. is led by CEO Peter A. Altman, employs 17 people, headquartered in US, publicly traded since 1996.

BioCardia, Inc. (BCDA) stock trades at $1.07 with a market capitalization of $15.93M. The stock is valued at a price-to-earnings (P/E) ratio of -1.54, price-to-book of 5.24, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.75 and $1.80, and currently trades 40.6% below its 52-week high.

On profitability, BioCardia, Inc. generates a return on equity (ROE) of -569.36%, return on capital employed of -273.70%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1178.66 +0.77% JNJ Johnson & Johnson $260.92 +1.73% ABBV AbbVie Inc. $277.08 +1.71% MRK Merck & Company, Inc. Common Stock (new) $146.45 +2.86% UNH UnitedHealth Group Incorporated Common Stock (DE) $377.83 +1.86% NVS Novartis AG $143.26 +0.10% AZN AstraZeneca PLC $159.37 +0.37% TMO Thermo Fisher Scientific Inc $660.73 +1.34% AMGN Amgen Inc. $417.21 +2.40% GILD Gilead Sciences, Inc. $151.27 +2.83% ABT Abbott Laboratories $99.17 +0.69% NVO Novo Nordisk A/S $38.42 +0.62%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides